Progyny Inc
$ 20.78
-2.49%
24 Feb - close price
- Market Cap 1,837,170,000 USD
- Current Price $ 20.78
- High / Low $ 21.34 / 20.59
- Stock P/E 34.37
- Book Value 6.55
- EPS 0.62
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.11 %
- 52 Week High 28.75
- 52 Week Low 17.98
About
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$30.91
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-08 | 2023-02-27 |
| Reported EPS | 0.45 | 0.48 | 0.48 | 0.42 | 0.4 | 0.17 | 0.17 | 0.13 | 0.16 | 0.15 | 0.18 | 0.03 |
| Estimated EPS | 0.1251 | 0.16 | 0.4457 | 0.37 | 0.13 | 0.17 | 0.13 | 0.11 | 0.12 | 0.1 | 0.07 | 0.01 |
| Surprise | 0.3249 | 0.32 | 0.0343 | 0.05 | 0.27 | 0 | 0.04 | 0.02 | 0.04 | 0.05 | 0.11 | 0.02 |
| Surprise Percentage | 259.7122% | 200% | 7.6958% | 13.5135% | 207.6923% | 0% | 30.7692% | 18.1818% | 33.3333% | 50% | 157.1429% | 200% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PGNY
2026-02-19 21:50:00
This article provides an analysis of Progyny Inc. (NASDAQ: PGNY)'s price dynamics and execution-aware positioning, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies for various risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels. The analysis emphasizes the utility of AI models for risk management and position sizing.
2026-02-19 07:27:35
Progyny (NASDAQ:PGNY) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting earnings per share of $0.38. The company currently holds a "Moderate Buy" consensus rating from Wall Street with an average target price of $29.80, and institutional investors have a high ownership stake of approximately 94.93%. Recent institutional activity indicates strong interest, with firms like Wellington Management significantly increasing their positions.
2026-02-18 11:27:54
CenterBook Partners LP significantly increased its stake in Progyny, Inc. by 272.7% in Q3, acquiring 310,516 additional shares to hold a total of 424,393 shares valued at approximately $9.13 million. Other institutional investors like Ameriprise, Jupiter Asset Management, Nomura Holdings Inc., Fort Washington Investment Advisors, and Principal Financial Group Inc. also raised their positions, contributing to Progyny's high institutional ownership of 94.93%. Analysts currently have a "Moderate Buy" rating on Progyny, with a consensus target price of $29.80 against its current trading price near $20.35.
2026-02-18 10:27:54
The Public Sector Pension Investment Board increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 40.9% in the third quarter, acquiring an additional 104,026 shares, bringing its total holdings to 358,234 shares valued at approximately $7.71 million. Several other institutional investors also adjusted their positions in the company. Analysts maintain a "Moderate Buy" consensus rating for Progyny, with a target price of $29.80.
2026-02-17 09:57:40
Progyny Inc (NASDAQ:PGNY) has successfully passed the "Caviar Cruise" quality investing screen, which identifies companies with strong competitive strengths, consistent profitability, a sound financial condition, and high returns on capital. The company excels in sales and EBIT growth, capital utilization with an exceptional ROIC of 30.82%, and maintains a debt-free balance sheet with high-grade earnings. This positions Progyny as a strong candidate for long-term, quality-centered investment portfolios, despite its premium valuation.
2026-02-13 17:27:53
Progyny, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2025, on February 26, 2026, after market close, followed by a conference call. The company, a global leader in women's health and family building solutions, has seen insider trading activity and institutional investor shifts, with recent analyst ratings and price targets also noted. An audio replay of the call will be available, and additional company information can be found on its website.
